A detailed history of Royal Bank Of Canada transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 5,808 shares of KOD stock, worth $37,345. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,808
Previous 3,188 82.18%
Holding current value
$37,345
Previous $7,000 114.29%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.2 - $3.25 $5,764 - $8,515
2,620 Added 82.18%
5,808 $15,000
Q2 2024

Aug 14, 2024

SELL
$2.29 - $4.48 $2,812 - $5,501
-1,228 Reduced 27.81%
3,188 $7,000
Q1 2024

Nov 05, 2024

BUY
$3.01 - $7.45 $3,696 - $9,148
1,228 Added 38.52%
4,416 $23,000
Q1 2024

May 15, 2024

SELL
$3.01 - $7.45 $18,854 - $46,666
-6,264 Reduced 58.65%
4,416 $23,000
Q4 2023

Feb 14, 2024

BUY
$1.4 - $3.24 $4,517 - $10,455
3,227 Added 43.3%
10,680 $32,000
Q3 2023

Nov 14, 2023

BUY
$1.8 - $7.49 $7,110 - $29,585
3,950 Added 112.76%
7,453 $13,000
Q2 2023

Aug 14, 2023

BUY
$4.3 - $9.48 $6,346 - $13,992
1,476 Added 72.82%
3,503 $24,000
Q1 2023

May 15, 2023

SELL
$4.81 - $8.88 $90,413 - $166,917
-18,797 Reduced 90.27%
2,027 $12,000
Q4 2022

Feb 14, 2023

BUY
$6.52 - $8.05 $86,272 - $106,517
13,232 Added 174.29%
20,824 $149,000
Q3 2022

Nov 14, 2022

BUY
$7.57 - $12.5 $27,062 - $44,687
3,575 Added 89.0%
7,592 $59,000
Q2 2022

Aug 15, 2022

SELL
$5.04 - $9.48 $8,779 - $16,514
-1,742 Reduced 30.25%
4,017 $31,000
Q1 2022

May 16, 2022

SELL
$7.09 - $89.45 $41,901 - $528,649
-5,910 Reduced 50.65%
5,759 $45,000
Q4 2021

Feb 14, 2022

BUY
$80.85 - $128.49 $352,829 - $560,730
4,364 Added 59.74%
11,669 $990,000
Q3 2021

Nov 15, 2021

SELL
$81.97 - $106.94 $980,033 - $1.28 Million
-11,956 Reduced 62.07%
7,305 $701,000
Q2 2021

Aug 16, 2021

BUY
$77.2 - $126.54 $1.49 Million - $2.44 Million
19,261 New
19,261 $1.79 Million

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $335M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.